Baker Bros. Advisors LP Aerie Pharmaceuticals Inc Transaction History

Baker Bros. Advisors LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$56.15 - $73.9 $3.38 Million - $4.45 Million	-60,155 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$47.85 - $70.45 $7.44 Million - $11 Million	-155,500 Reduced 72.11%	60,155 $4.06 Million
Q1 2018 May 15, 2018	SELL	$51.15 - $61.0 $4.28 Million - $5.11 Million	-83,701 Reduced 27.96%	215,655 $11.7 Million
Q3 2017 Nov 14, 2017	BUY	$48.6 - $60.1 $14.5 Million - $18 Million	299,356	299,356 $14.5 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.